Back

PRIME Education, Inc. (PRIME®)

  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Problem Solving
  • Tyrosine Kinase Inhibitors

Applying the Latest Clinical Evidence Into Frontline CML Treatment Decisions

With multiple tyrosine kinase inhibitors (TKIs) now available for chronic myeloid leukemia (CML), care teams face complex decisions about selecting the optimal frontline therapy, individualizing dosing, and balancing efficacy with tolerability for diverse patient populations. In parallel, the need for timely and accurate molecular monitoring adds another layer of challenge, including interpreting response milestones, making treatment adjustments, and evaluating when patients may be ready for treatment-free remission (TFR). This interactive, case-based challenge immerses hematology/oncology teams in realistic clinical scenarios that test their ability to navigate these decision points. Hone your skills in evaluating patient and disease factors, applying molecular monitoring data, and determining next steps in care, whether that means optimizing TKI therapy, adjusting for adverse events, or counseling patients on TFR eligibility. Don’t miss this opportunity to sharpen your multidisciplinary problem-solving skills and leave with actionable strategies to enhance patient-centered CML care.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AAPA Category 1 Credit™Up to 0.25 creditsAMA PRA Category 1 Credit™Up to 0.25 creditsNursingUp to 0.25 creditsPharmacyUp to 0.25 credits

MOC types

No MOC

FDA REMS

No

Qualifies for MIPS

No

Pricing

Free

Reported to ACCME by the provider

  • Case-based learning
  • Credit · Up to 0.25 credits
  • Commercial Support
  • Released
    Dec 19, 2025
  • Last day to claim credit
    Dec 19, 2026 2 months left